Using gut bacteria to improve treatment for rheumatoid arthritis
Employing the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapy
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-10686275
This study is looking at how the bacteria in your gut might affect how well rheumatoid arthritis treatments, like methotrexate, work for you, with the goal of finding better, more personalized options for managing your condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10686275 on ClinicalTrials.gov |
What this research studies
This research investigates how the gut microbiome influences the effectiveness of rheumatoid arthritis (RA) therapies, particularly methotrexate, which is commonly used to treat this autoimmune condition. By studying the variations in gut bacteria among patients, the research aims to identify why some individuals do not respond well to standard treatments. The approach involves analyzing the gut microbiome's impact on drug absorption and effectiveness, potentially leading to more personalized treatment strategies for RA patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with moderate to severe rheumatoid arthritis who are starting treatment with methotrexate.
Not a fit: Patients with rheumatoid arthritis who are already responding well to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for rheumatoid arthritis patients by tailoring therapies based on individual gut microbiome profiles.
How similar studies have performed: Other research in pharmacomicrobiomics has shown promise in enhancing treatment efficacy in various conditions, suggesting that this approach could be beneficial for rheumatoid arthritis as well.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHER, JOSE U. — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: SCHER, JOSE U.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.